7,192 Shares in LivaNova PLC (NASDAQ:LIVN) Purchased by Nomura Holdings Inc.

Nomura Holdings Inc. purchased a new position in LivaNova PLC (NASDAQ:LIVN) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 7,192 shares of the company’s stock, valued at approximately $333,000.

A number of other hedge funds have also bought and sold shares of the company. Russell Investments Group Ltd. boosted its holdings in LivaNova by 17.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after purchasing an additional 219 shares during the period. Summit Investment Advisors Inc. boosted its stake in LivaNova by 1.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock valued at $780,000 after acquiring an additional 289 shares during the period. Xponance Inc. boosted its stake in LivaNova by 6.1% in the fourth quarter. Xponance Inc. now owns 7,762 shares of the company’s stock valued at $359,000 after acquiring an additional 445 shares during the period. Mariner LLC boosted its stake in LivaNova by 8.4% in the fourth quarter. Mariner LLC now owns 5,741 shares of the company’s stock valued at $266,000 after acquiring an additional 446 shares during the period. Finally, Invesco Ltd. boosted its stake in LivaNova by 0.6% in the fourth quarter. Invesco Ltd. now owns 111,374 shares of the company’s stock valued at $5,158,000 after acquiring an additional 667 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on LIVN shares. Mizuho decreased their target price on LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. The Goldman Sachs Group reduced their price target on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a report on Monday, March 3rd. Needham & Company LLC reissued a “buy” rating and set a $64.00 price target on shares of LivaNova in a report on Tuesday, May 13th. Barclays reduced their price target on shares of LivaNova from $56.00 to $55.00 and set an “equal weight” rating for the company in a report on Thursday, May 8th. Finally, Wolfe Research raised shares of LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 price target for the company in a report on Tuesday. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $59.29.

LivaNova Stock Performance

Shares of NASDAQ LIVN opened at $43.18 on Friday. The company has a market cap of $2.35 billion, a PE ratio of 102.81 and a beta of 0.84. The stock has a 50 day simple moving average of $38.74 and a 200-day simple moving average of $44.71. LivaNova PLC has a 12-month low of $32.48 and a 12-month high of $61.94. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.